Clin2
NCT06860984Possibly a fitRecruiting

Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Biliary Disease

Treatments studied

Part of Digestive system clinical trials.

This phase 3 trial tests duloxetine for preventing pancreatitis after ERCP in adults with normal baseline amylase/lipase and without certain comorbidities.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
44 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • Age > 18 years
  • Indication for ERCP due to suspected pancreato-biliary disorders
  • Normal blood amylase and lipase before ERCP
  • No uncontrolled diabetes, severe bleeding, impaired renal function, severe heart disease
  • No prior biliary or pancreatic sphincterotomy/dilatation/stenting
  • Not pregnant or nursing
  • No pancreatitis admission before ERCP

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05141916Recruiting
Testing the best way to evaluate suspected bile duct stones

This trial studies how doctors should best check and manage people with suspected bile duct stones. It may help improve the accuracy and safety of next-step testing and treatment.

Calgary, Alberta
NCT06861010Recruiting· Phase 3
Ondansetron to prevent pancreatitis after ERCP

This trial tests whether ondansetron, a medicine that helps control nausea and vomiting, can reduce the risk of pancreatitis (inflammation of the pancreas) after an ERCP procedure. If you are scheduled for an ERCP and do not have certain health issues, you may be able to join.

Tanta
NCT07329790Not yet recruiting
National study on post-ERCP pancreatitis prevention

This trial is studying how often pancreatitis happens after a common bile duct procedure called ERCP, and how a standard safety protocol might help prevent it. It aims to include people who need a therapeutic ERCP (treatment, not just diagnosis) to learn more about safe practices.

NCT06623513Not yet recruiting· Phase 2
Comparing two pain medicines for pancreatitis prevention after ERCP

This trial tests whether parecoxib or indomethacin works better at preventing pancreatitis, a common complication after a procedure called ERCP. Participants will receive one of the two medicines before the procedure, and the study will track which one is safer and more effective.

NCT05252754Recruiting· Phase 3
Medicines to prevent pancreas swelling after ERCP

This Phase 3 study tests whether putting an anti-inflammatory medicine into the rectum (indomethacin) plus taking an immune-suppressing pill (tacrolimus) works better than using the two medicines in a different combination to prevent pancreatitis after an ERCP procedure. If you qualify, you may be assigned to one of the treatment options to lower your risk of post-ERCP pancreas inflammation.

Baltimore, Maryland
NCT05667987Recruiting
Lidocaine to help prevent pancreas inflammation after ERCP

This study tests whether giving lidocaine during an ERCP procedure can lower the risk of a painful complication called pancreatitis. If you’re scheduled for ERCP with a “never-treated” opening, this trial may see if lidocaine helps you avoid post-procedure pancreas inflammation.

Paris

Hear when a new Biliary Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.